Abstract: Provided is an electrophotographic belt of an endless shape including a substrate, wherein the substrate contains a polyimide resin and carbon nanotubes, wherein a content of the carbon nanotubes in the substrate is 15 vol % or less with respect to a total volume of the polyimide resin, wherein the substrate has a tensile strength of 200 MPa or more in each of a peripheral direction thereof and a direction perpendicular to the peripheral direction, and wherein the substrate has a thermal conductivity of 0.9 W/(m·K) or more in a thickness direction thereof.

Abstract: A wave receiving mechanism includes: a shaft driving a hydraulic pump; and a wave receiving member including an arm and wave receiving plate, the arm unrotatably attached to the shaft, the plate being at the arm receiving a wave force, the wave receiving member swinging about the shaft by receiving the wave force and turning the shaft turn. The arm includes first and second arm portions, and a bendable portion, the first arm portion unrotatably attached to the shaft, the second arm portion being at the plate, the bendable portion coupling the first and second arm portions. When a swing angle of the first arm portion is less than a first predetermined angle, the bendable portion makes the arm portions swing integrally. When the swing angle of the first arm portion is the predetermined angle, the bendable portion allows the second arm portion to bend relative to the first.

Abstract: The present invention provides an improved adeno-associated virus (AAV)-binding protein having enhanced stability, especially, heat stability, acid stability and alkali stability, of an AAV-binding protein, a method for producing the improved AAV-binding protein, and an AAV adsorbent using the same.

Abstract: A wave power generation system includes: a hydraulic pump device configured to operate by force of a wave to discharge an operating liquid to a main passage; a hydraulic motor device configured to be rotated by the operating liquid flowing through the main passage; a power generator configured to be driven by the hydraulic motor to generate electric power; and a heat exchanger device configured to perform heat exchange of the operating liquid. The heat exchanger device includes a heat exchange motor device connected to the main passage through a sub passage and configured to be operated by the operating liquid introduced through the sub passage, a refrigerant pump device driven by the heat exchange motor device and configured to suck and discharge a refrigerant liquid, and a heat exchanger to which the refrigerant liquid discharged from the heat exchange pump device and the operating liquid are introduced.

Abstract: A wave receiving plate is pivotably supported by a support device in the wave force generation system and includes a flexible plate in at least a part of the wave receiving plate.

Abstract: A wave power generation system includes: a hydraulic pump device configured to operate by force of a wave to discharge an operating liquid to a main passage; a hydraulic motor device configured to be rotated by the operating liquid flowing through the main passage; a power generator configured to be driven by the hydraulic motor to generate electric power; and a heat exchanger device configured to perform heat exchange of the operating liquid. The heat exchanger device includes a heat exchange motor device connected to the main passage through a sub passage and configured to be operated by the operating liquid introduced through the sub passage, a refrigerant pump device driven by the heat exchange motor device and configured to suck and discharge a refrigerant liquid, and a heat exchanger to which the refrigerant liquid discharged from the heat exchange pump device and the operating liquid are introduced.

Abstract: A wave power generation system includes a wave receiving member, ram cylinder hydraulic pump device, change value sensor, accumulator device, hydraulic motor, power generator, and controller. The member is arranged near a virtual reflection surface that reflects a coming incident wave. The controller sets a torque command used when the generator generates electric power. Based on a differential value of a change value detected by the sensor and changes in accordance with a swing amount of the member, the controller determines whether the member is swinging toward a first or second side in a swing direction. When the controller determines the member is swinging toward the second side by receiving force of a reflected wave reflected by the virtual reflection surface, the controller changes the torque command from the command set when the controller determines the member is swinging toward the first side by receiving force of the incident wave.

Abstract: A wave receiving plate is pivotably supported by a support device in the wave force generation system and includes a flexible plate in at least a part of the wave receiving plate.

Abstract: A wave power generation system includes a wave receiving member, ram cylinder hydraulic pump device, change value sensor, accumulator device, hydraulic motor, power generator, and controller. The member is arranged near a virtual reflection surface that reflects a coming incident wave. The controller sets a torque command used when the generator generates electric power. Based on a differential value of a change value detected by the sensor and changes in accordance with a swing amount of the member, the controller determines whether the member is swinging toward a first or second side in a swing direction. When the controller determines the member is swinging toward the second side by receiving force of a reflected wave reflected by the virtual reflection surface, the controller changes the torque command from the command set when the controller determines the member is swinging toward the first side by receiving force of the incident wave.

Abstract: A wave receiving mechanism includes: a shaft driving a hydraulic pump; and a wave receiving member including an arm and wave receiving plate, the arm unrotatably attached to the shaft, the plate being at the arm receiving a wave force, the wave receiving member swinging about the shaft by receiving the wave force and turning the shaft turn. The arm includes first and second arm portions, and a bendable portion, the first arm portion unrotatably attached to the shaft, the second arm portion being at the plate, the bendable portion coupling the first and second arm portions. When a swing angle of the first arm portion is less than a first predetermined angle, the bendable portion makes the arm portions swing integrally. When the swing angle of the first arm portion is the predetermined angle, the bendable portion allows the second arm portion to bend relative to the first.

Abstract: The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments.

Abstract: The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments.

Abstract: This invention provides compounds including peptides and peptidomimetics that can be used to treat cell proliferative disorders, such as those associated with benign and malignant tumor cells. While the invention is not limited to any particular mechanism, the compounds of the invention appear to function at least in part by inhibiting G2 cell cycle checkpoint. Thus, invention compounds can be used to inhibit cell growth alone or be used in combination with a nucleic acid damaging treatment to inhibit cell growth.

Abstract: The invention provides compounds having immune-modulating and/or anti-inflammatory and/or anti-viral activity, wherein compounds of the invention include peptides and peptidomimetics. The invention further provides methods of using immune-modulating and/or anti-inflammatory and/or anti-viral compounds of the invention. In particular, the invention provides methods for treating a disease related to an immune disorder or inflammation or viral infection by administering an amount of a G2-checkpoint-abrogating peptide or peptidomimetic sufficient to inhibit the disease.

Abstract: The invention provides compounds having immune-modulating and/or anti-inflammatory and/or anti-viral activity, wherein compounds of the invention include peptides and peptidomimetics. The invention further provides methods of using immune-modulating and/or anti-inflammatory and/or anti-viral compounds of the invention. In particular, the invention provides methods for treating a disease related to an immune disorder or inflammation or viral infection by administering an amount of a G2-checkpoint-abrogating peptide or peptidomimetic sufficient to inhibit the disease.

Abstract: This invention provides compounds including peptides and peptidomimetics that can be used to treat cell proliferative disorders, such as those associated with benign and malignant tumor cells. While the invention is not limited to any particular mechanism, the compounds of the invention appear to function at least in part by inhibiting G2 cell cycle checkpoint. Thus, invention compounds can be used to inhibit cell growth alone or be used in combination with a nucleic acid damaging treatment to inhibit cell growth.

Abstract: The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments.

Abstract: The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments.

Abstract: The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments.

Abstract: The present disclosure provides methods for determining the sensitivity of cancerous cells to various anti-cancer therapies and predicting the efficacy of these therapies. Specifically, the present disclosure provides methods for predicting the efficacy of one or more candidate anti-cancer therapies in a patient, based on determining the sensitivity of the patient's cancerous cells after exposure to candidate anti-cancer therapies in vitro. The disclosure further provides methods for predicting the efficacy of candidate anti-cancer therapies by using an in vitro sensitivity test of the patient's cancerous cells and a surrogate in vivo efficacy test of the patient's cancerous cells grafted into a surrogate host. The disclosure further provides methods for selecting the most efficacious anti-cancer therapy(s) for a patient, thereby avoiding ineffective or unnecessary treatments.